Italian-based Stevanato Group, a producer of glass primary packaging and provider of integrated capabilities for combination products, has formed an agreement with Pfeiffer Vacuum Technologies to provide characterization testing of container-closure systems for the biopharma industry. 
 
U.S.-based Pfeiffer Vacuum Technologies specializes in leak testing and CCI technologies. The CCI analysis and testing services will take place at Stevanato Group’s state-of-the-art U.S. Technology Excellence Center (TEC) due to open in Boston in Q3 2020.
 
“The TEC-Pfeiffer Vacuum agreement combines our extensive expertise in glass primary packaging testing with proven CCI testing solutions for the biopharma market,” said Abizer Harianawala, site leader, Stevanato Group TEC. “Over the years biopharma companies have been facing increasingly stricter standard requirements in terms of reliability of CCI testing. Working with Pfeiffer Vacuum Technologies will allow us to support the quality, integrity and effectiveness of sensitive drugs, preventing issues such as moisture, oxygen or microbial contamination.” 
 
The TEC will provide analytical and testing services related to container closure systems and drug delivery devices, as well as delivering a set of customized analytics and testing services for biopharma companies’ drug formulation and manufacturing processes. 
 
“Partnering Pfeiffer Vacuum’s industry leadership in CCI technologies with Stevanato Group’s strong experience of the biopharma industry and glass packaging testing is a win-win for both companies as well as packaging suppliers and creates a center of excellence in parenteral drug packaging,” said Brian Pahl, president, Pfeiffer Vacuum Technologies.